黃葵膠囊聯合醋酸潑尼松治療原發性腎病綜合征的療效

王艷秋

摘要：目的 ?觀察黃葵膠囊聯合醋酸潑尼松治療原發性腎病綜合征臨床療效。方法 ?選取2018年8月～2019年8月在我院診治的96例原發性腎病綜合征患者為研究對象，采用隨機數字表法分為對照組和觀察組，各48例。對照組采用醋酸潑尼松治療，觀察組在醋酸潑尼松治療基礎上給予黃葵膠囊治療，比較兩組臨床總有效率、治療前后腎功能指標[尿素氮（BUN）、24h尿蛋白定量、血肌酐（SCr）]、血脂指標[膽固醇（CHO）、甘油三酯（TG）、低密度脂蛋白（LDL）]、血漿白蛋白以及臨床不良反應（失眠、高血糖、藥源性高血壓、惡心）發生情況。結果 ?觀察組臨床治療總有效率為93.75%，高于對照組的81.25%，差異有統計學意義（P<0.05）;治療后兩組BUN、24h尿蛋白定量、SCr、CHO、TG、LDL均低于治療前，且觀察組低于對照組，差異有統計學意義（P<0.05）;治療后兩組血漿白蛋白均高于治療前，且觀察組高于對照組，差異有統計學意義（P<0.05）;觀察組臨床不良反應發生率為8.33%，與對照組的10.41%比較，差異無統計學意義（P>0.05）。結論 ?黃葵膠囊聯合醋酸潑尼松治療原發性腎病綜合征有效率高，患者腎功能改善明顯，可一定程度降低血脂，且臨床不良反應少，聯合治療安全可靠。

關鍵詞：黃葵膠囊;醋酸潑尼松;原發性;腎病綜合征

中圖分類號：R692 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 文獻標識碼：A ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? DOI：10.3969/j.issn.1006-1959.2020.17.051

文章編號：1006-1959（2020）17-0168-03

Abstract：Objective ?To observe the clinical efficacy of Huangkui capsule combined with prednisone acetate in the treatment of primary nephrotic syndrome.Methods ?A total of 96 patients with primary nephrotic syndrome who were diagnosed and treated in our hospital from August 2018 to August 2019 were selected as the research objects. They were divided into control group and observation group by random number table method， with 48 cases in each group. The control group was treated with prednisone acetate， and the observation group was treated with Huangkui capsules on the basis of prednisone acetate treatment. The total clinical effective rate and renal function indexes before and after treatment were compared between the two groups [urea nitrogen （BUN）， 24h urine protein quantification， Serum creatinine （SCr）]， blood lipid indexes [cholesterol （CHO）， triglycerides （TG）， low-density lipoprotein （LDL）]， plasma albumin， and clinical adverse reactions （insomnia， hyperglycemia， drug-induced hypertension， nausea） occurs.Results ?The total effective rate of clinical treatment in the observation group was 93.75%， which was higher than 81.25% in the control group，the difference was statistically significant （P<0.05）; after treatment， the two groups had low BUN， 24h urine protein quantification， SCr， CHO， TG， and LDL before treatment， and the observation group was lower than the control group， the difference was statistically significant （P<0.05）; after treatment， the plasma albumin of the two groups was higher than before treatment， and the observation group was higher than the control group， the difference was statistically significant （P<0.05）; The incidence of clinical adverse reactions in the observation group was 8.33%， which was not statistically significant compared with 10.41% in the control group （P>0.05）.Conclusion ?Huangkui capsule combined with prednisone acetate had a high effective rate in the treatment of primary nephrotic syndrome. The patient's renal function was improved significantly， blood lipids could be reduced to a certain extent， and clinical adverse reactions were few. The combined treatment was safe and reliable.

Key words：Huangkui capsule;Prednisone acetate;Primary;Nephrotic syndrome

原發性腎病綜合征（primary nephrotic syndrome）是臨床腎內科常見疾病，與細胞免疫功能異常相關。目前，臨床常規給予潑尼松及細胞毒類藥物治療，不僅治療周期長，且長期應用臨床副作用明顯，停藥后容易復發，嚴重影響臨床治療效果。隨著中醫學在臨床疾病治療中的廣泛應用，在常規治療基礎上聯合中醫藥治療原發性腎病綜合征可一定程度改善療效。目前，已有黃葵膠囊聯合醋酸潑尼松治療原發性腎病綜合征的相關研究，但是關于其臨床有效率、安全性以及對腎功能的影響等方面存在差異[1]。……